Deal volume fell by 24 per cent to its lowest level since mid-2020, despite predictions of a surge in activity in the wake of ...

Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

Prespecified subgroup analyses showed that primary surgery conferred greater benefits for patients with stage III disease and ...

Neglected tropical diseases (NTDs) are a diverse group of conditions1 that still affect 1 billion people, mainly vulnerable populations in underserved ...

Global Akeega sales will reach $676 million by 2030, while Talzenna and saruparib reach $618 million and $628 million ...

GlaxoSmithKline (GSK – Research Report) received a Hold rating and a $41.00 price target from Berenberg Bank analyst Kerry Holford today. Confident Investing Starts Here: Easily ...

Among patients who received four-drug consolidation therapy, 84% had measurable residual disease (MRD)-negative status before ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

These mutated diseases defy the power of antibiotics. Are illnesses really mutating so fast that we can’t stay ahead of them?

There have been important recent advances in the management of Crohn's disease, including new classes of biological or small molecule therapies, an appreciation that endoscopic mucosal healing results ...

Take a closer look at London's biotech hub – renowned for its thriving life sciences ecosystem and world-class infrastructure ...